Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sunshine Act Hits Daylight Savings Time; PhRMA Seeks Extension For Physician Payment Reporting

This article was originally published in RPM Report

Executive Summary

CMS is late on its rules implementing the “Sunshine Act,” and industry hopes that means they have more time before they have to comply with the law. Without the rules, they may be operating in the dark.

You may also be interested in...



Physician Payments Sunshine Rule From CMS Expected By Year's End

Pharmaceutical companies will have a little more than a year to put together data to comply with CMS regulations for reporting payments made to physicians if the agency meets its current timeline for issuing the rules.

Lilly Outside "Faculty" Is Headed By 22 Physicians Receiving $50,000 Or More

The most highly paid Lilly outside physician consultant in the first quarter of 2009 - San Jose, Calif., psychiatrist Manoj Waikar ($70,050) - says he was convinced that the public listing of financial ties was a good idea when his patients said they approved of his work with pharmaceutical companies

Supreme Court Seems To Support Government’s Later Dismissal Of False Claims Act Cases

Justices cite changing circumstances, constitutional concerns in preventing government from seeking dismissal of a case in which it initially declined to intervene. They also question whether government should intervene before moving to dismiss.

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS080907

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel